Products Affected - Description
Thrombin JMI, Pfizer
5,000 unit, Epistaxis kit, 1 count (NDC 60793-0205-05)
Reason for the Shortage
- Pfizer states the reason for the shortage is manufacturing delay.
- Recombinant thrombin topical solution products (Recothrom) are available and not affected by this shortage.
Thrombin JMI, Pfizer
5,000 unit, syringe spray kit, 1 count (NDC 60793-0705-05)
5,000 unit, vial, 1 count (NDC 60793-0215-05)
20,000 unit, pump spray kit, 1 count (NDC 60793-0217-21)
20,000 unit, syringe spray kit, 1 count (NDC 60793-0217-22)
20,000 unit, vial, 1 count (NDC 60793-0217-20)
Estimated Resupply Dates
Pfizer has Thrombin JMI 5,000 unit epistaxis kits on back order and the company estimates a release date of early-December 2016.
November 22, October 31 and 8, September 26 and 7, August 23, July 29 and 12, June 30, May 16, 10 and 4, April 18 and 7, March 11, February 29, 22 and 10, January 29 and 6, 2016; December 21 and 11, November 24, October 12, September 25 and 9, July 22, 2015, University of Utah, Drug Information Service. Copyright 2016, Drug Information Service, University of Utah, Salt Lake City, UT.
This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.
« Back to Drug Shortage Product Bulletins